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ABSTRACT 
Placental dysfunction has a deleterious influence on fetal size and is associated 
with higher rates of both perinatal morbidity and mortality. This association 
underpins the strategy of fetal size evaluation as a mechanism to identify 
placental dysfunction and prevent stillbirth. The optimal method of routine SGA 
detection remains to be clarified with choices between symphyseal-fundal 
height estimation versus routine third trimester ultrasound, various formulae for 
fetal weight estimation by ultrasound and the use of national, customized or 
international fetal growth references. Despite this controversy, the strategy of 
SGA detection is undermined by data demonstrating that the relationship 
between fetal size and adverse outcome weakens significantly with advancing 
gestation such that near term, the majority of stillbirths and adverse perinatal 
outcomes occur in normally-sized fetuses. The use of maternal serum 
biochemical and Doppler parameters near term appears to be superior to fetal 
size in the identification of fetuses compromised by placental dysfunction and 
at increased risk of damage or demise. Multiparameter models and predictive 
algorithms using maternal risk factors, biochemical and Doppler parameters 





Stillbirth conventionally refers to the demise of a fetus in the second half of 
pregnancy. Not only is stillbirth a devastating obstetric outcome, it is a potential 
trigger to major economical and psychological consequences for women, 
families, health-care providers and communities. There are an estimated 4.2 
million women living with depression secondary to a previous fetal death (1). 
Global estimates of stillbirth rate usually take into account only those occurring 
after 28 weeks, as there is some inter-country variation in the classification of 
early stillbirth. In 2015, the estimated average global SB rate was 18.4 per 
1,000 births, with an approximate annual total of 2.6 million late fetal deaths (2). 
This equates to more than 7,000 families worldwide experiencing the burden of 
a fetal loss every day, with 80% of cases occurring in South Asia and sub-
Saharan Africa - especially in rural settings and conflict zones (3). In these low 
and middle income countries, half of stillbirths are diagnosed in labor, in 
contrast to high-income countries only 16% of stillbirths occurred intrapartum 
(2,4). 
Although the majority of stillbirths at term are labelled ‘unexplained’, this is often 
repeatedly and incorrectly interpreted as being unpreventable. In a total of 18 
national reports from several different economic zones, only 7.4% of stillbirths 
were attributable to congenital anomalies (3). Impaired fetal growth secondary 
to placental dysfunction is considered to be one of the main reasons for 
perinatal morbidity and mortality. Fetuses weighing below the 10th centile are 
found approximately 2 to 3-times more frequently amongst stillbirths than live 
births (5). Small for gestational age (SGA) infants also contributed to 22% of 
neonatal deaths in a recent study of over 22 million infants born in low and 
middle income countries (6). Combined with the finding that up to 8 in 10 SGA 
neonates are born at term, it has become routine clinical practice to screen for 
SGA fetuses in order to detect placental dysfunction and prevent of adverse 
pregnancy outcomes (7). In this article, we discuss the rationale for the strategy 
of stillbirth prevention by fetal size-based screening and management in the 
light of contemporary scientific evidence. 
 
ESTIMATED FETAL WEIGHT 
Classically, screening for SGA has been embedded into routine prenatal care 
by assessing maternal risk factors identification, serial symphyseal-fundal 
height measurements and identifying pregnancy complications such as 
preeclampsia. Increased risk of placental dysfunction identified by any of these 
means usually triggers ultrasound evaluation for fetal growth and well-being (8). 
This is still the strategy currently practiced in the majority of obstetric units (9), 
although an universal third trimester ultrasound screening approach has been 
shown to double the detection of SGA fetuses and triple the detection of severe 
SGA with estimated fetal weight (EFW) below the 3rd centile for gestational age 
(10,11). Ultrasound assessment under these circumstances follows two main 
steps: measurement of fetal biometry to calculate EFW and plotting the EFW 
on a chart to establish a fetal weight centile for the given gestational age. 
EFW formulae 
There are currently more than 60 published single or multi-parameter formulae 
to estimate fetal weight. A recent study using a population of more than 5,000 
non-anomalous singleton pregnancies scanned between 22 to 43 weeks and 
within days of birth evaluated the accuracy of EFW formulae (12). The authors 
showed that EFW calculated by Hadlock et al.’s 1985 formula (13), which uses 
head circumference (HC), abdominal circumference (AC) and femur length (FL) 
predicts birthweight within 10% in 80% of pregnancies even in when SGA or 
large for gestational age (12). Similarly, the same Hadlock formula performed 
best in multiple pregnancy with 70% of EFW estimated within 10% of birth 
weight (14). 
 
FETAL SIZE REFERENCES/STANDARDS 
Even though EFW can be calculated with relative accuracy by ultrasound fetal 
biometry and use of the correct fetal weight, this value will only be clinically 
useful when plotted on a normal range of EFW for gestational age to establish 
the fetal weight centile. Several charts have been developed with this purpose 
– some advocating references for a specific geographical region, some 
proposing customization taking into consideration clinical characteristics and 
others developed with the objective of being international reference standards. 
National/Local charts 
Locally developed reference charts have been widely used on the basis that 
they account for variations in environment, ethnicity and stature between 
different populations. Although this approach initially may seem to be 
reasonable on the basis that there are distinct rates of morbidity and mortality 
related to growth disorders across the world, there are many aspects that must 
be considered before adopting such local/national charts. First is related to the 
method of construction, since local/national charts are generally constructed 
retrospectively based on birth weight databases rather than ultrasound 
biometry. Prospectively developed charts would be better able to avoid 
including women with occult or hidden morbidities (15). Furthermore, reference 
charts should be created from ultrasound EFW, especially at preterm 
gestations where birthweights are liable to be affected (lowered) by the 
pathology that resulted in preterm birth (16,17). Other issues with implementing 
regional charts is that there are currently at least 116 definitions of self-reported 
ethnicity in the biomedical literature (18), and that the latter is variably defined 
by different populations (19) and the increasing frequency of mixed ethnicity. 
The final barrier to the adoption of local/national charts is the lack of a real 
biological explanation for why geographical location or the maternal passport 
would result in differences in fetal growth. Where putative reasons are 
proposed for geographical variations in adult stature, the arguments for 
socioeconomical and nutritional origins for this variation outweigh possible 
genetic causes. 
Customized charts 
Some authors support the point of view that fetal weight charts should be 
adjusted for maternal constitutional characteristics, making it possible to 
estimate an individualized gestation related optimal weight (GROW) for each 
fetus (20,21). Proponents of this policy argue that this customization only takes 
in consideration physiological maternal variations rather than pathological 
variables which reflect health, social and economic disparities among 
populations. For example, a recent NICHD Fetal Growth Study prospectively 
evaluated 1,737 low-risk women and reported that fetal growth not only differed 
significantly by self-identified ethnic group, but also by marital status, level of 
education and annual income (22). At odds with this policy of customization is 
that many of the variables that are included in customization such as maternal 
age, weight and ethnicity are known to be associated with adverse pregnancy 
outcome and stillbirth suggesting that they are not physiological variables that 
should be used to ‘normalize’ poor fetal growth. Furthermore, artificially setting 
SGA rates at 10% by customization does not adequately reflect the known 
variation in neonatal malnutrition rates between low and middle income 
countries, as well as the higher rates of obesity in high income countries (15). 
These limitations explain why despite repeated evaluations, customization for 
fetal growth has not been shown to improve prediction and prevention of 
stillbirth. A cohort study conducted in almost one million pregnant women at 
term in Scotland failed to show that customization improved prediction of 
stillbirth when compared to non-customization (23). This same study 
demonstrated that EFW below the 25th centile would provide better prediction 
for increased risk of stillbirth than the 10th centile (Figure 1). 
International fetal growth standards 
Local and customized descriptive charts are fetal growth references, which 
should be differentiated from prescriptive fetal growth standards. The former 
show how fetuses from a determined population have grown at a particular 
time, while the latter are developed to reflect how healthy pregnant fetuses 
should grow when free from nutritional, environmental and health restrictions 
(15). Two charts were developed with the purpose of being international 
standards for fetal growth in healthy populations, the INTERGROWTH-21st 
project (24,25) and the World Health Organization (WHO) sponsored study 
(26). The former was constructed prospectively from 2,404 fetuses at low risk 
for adverse outcomes from 8 delimited geographical areas and following WHO 
recommendations for assessment of human size and growth (27). This design 
made it possible to better exclude potential confounders and to reach the 
conclusion that human fetal growth is similar across different nationalities in 
low-risk situation (28). On the other hand, the WHO study followed-up 1,387 
pregnant women from 10 countries, reported that fetal growth varied modestly 
between populations influenced by age, height, weight parity and fetal sex (22). 
This difference could be explained by the less stringent screening, sample 
recruitment methods and follow-up parameters used by the two studies. In 
particular, being hospital-based studies can introduce selection bias as patients 
attending may not be representative of the population. INTERGROWTH-21st 
has been compared to few local and customized references, with reported 
decreased rates of identification of SGA and LGA (21,29). It is relatively evident 
that international standards will result in variable rates of pathology depending 
on the populations to which they are applied – similar to international thresholds 
used for diagnosing chronic hypertension of diabetes mellitus. 
 
FETAL GROWTH VELOCITY 
Another strategy used to identify fetuses affected by placental dysfunction is to 
study the fetal growth velocity obtained by sequential scans in pregnancy. The 
advantages of this approach include avoidance of individual measurement 
errors by the use of multiple scans and also the possibility of better identifying 
at-risk fetuses through the differentiation of normal versus abnormal growth 
profiles. However, previous studies of fetal growth velocity have reported 
inconsistent results, probably because of the lack of consensus of what 
constitutes a suboptimal fetal growth velocity, whether this varies with 
gestational age and the relationship of growth velocity to adverse pregnancy 
outcome. The prospective TRUFFLE randomized controlled study 
prospectively evaluated 503 cases of severe fetal growth restriction between 
26 and 32 weeks and reported that fetal growth was not predictive of adverse 
outcome (30,31). Conversely, the POP study, which evaluated 3,977 pregnant 
women for selective or universal ultrasound in the third trimester, showed that 
AC growth velocity was associated with adverse pregnancy outcome, but only 
in 4% of the sample where the EFW was already below the 10th centile, but not 
in appropriate for gestational age (AGA) fetuses (11). In a larger retrospective 
study, Ciobanu et al. showed that the predictive performance of a single EFW 
at 35 to 36+6 weeks for SGA was not improved neither by the addition of 
estimated growth velocity between 20 and 36 weeks in a population of 44,000 
pregnant patients (32) nor between 32 and 36 weeks in a 14,000 patient sample 
(33). 
 
RELATIONSHIP BETWEEN FETAL SIZE AND STILLBIRTH 
There is a an overrepresentation of SGA fetuses amongst stillbirths, especially 
those that occur before 32 weeks of gestation, where 70% have birthweights 
below the 10% centile (4). The latter observation combined with the finding that 
up to 80% of SGA neonates are born at term, it has become routine clinical 
practice to screen for SGA fetuses in order to detect placental dysfunction and 
prevent of adverse pregnancy outcomes (7). However, this strategy is 
undermined by the finding in several large population-based studies, that only 
30-40% of stillbirth after 32 weeks are SGA (4,29,34,35) (Figure 2). 
Confounding the relationship between SGA and stillbirth is the finding that 
intrauterine stillbirths progressively lose 20-25% of bodyweight in utero through 
maceration and after being delivered due to shrinkage in fetal mass by 
dehydration (36). Accounting for postmortem fetal weight loss suggests that the 
true prevalence of SGA birth in stillbirth at term is nearer 20-25%, meaning that 
the majority of adverse pregnancy outcomes occur in appropriately grown 
fetuses. 
Definition of fetal growth restriction 
Small for gestational age is the statistical deviation of fetal size from a reference 
standard, with an agreed threshold of less than the 10th centile. In contrast, fetal 
growth restriction (FGR) is a functional problem caused by uteroplacental 
insufficiency, where the definition should ideally include functional biophysical 
and biochemical indices of placental function. Uteroplacental dysfunction 
resulting in FGR is far more strongly associated to perinatal morbidity and 
mortality than SGA. Until recently there has been no gold standard for its 
diagnosis and many definitions have been used in the medical literature, 
making it difficult to compare results among published papers (37). In 2016, a 
definition of FGR through a Delphi procedure stressed marked differences 
between early and late-onset FGR. The expert consensus recommended 
taking into consideration not only fetal biometric parameters, but also functional 
ones such as Doppler indices and cardiotocography (Table 1). For the first time, 
there was consensus that placental dysfunction resulting in fetal hypoxemia in 
FGR may occur in fetuses with AC/EFW above the 10th centile. The latter was 
marked by marked reduction in AC/EFW growth centiles and/or fetal Doppler 
abnormalities (37). The author’s opinion was that the updated definition would 
better differentiate pathological growth restricted fetuses from the 
constitutionally small and healthy ones (37). 
Although early and late-onset fetal growth restriction were defined as occurring 
before or after 32 weeks’ gestation, it’s important to emphasize that they are 
not different disorders, but instead the consequences or signs of placental 
dysfunction following distinct patterns depending on the gestational age at 
onset of placental dysfunction (38,39). Early-onset FGR pregnancies 
diagnosed before 32 weeks are less prevalent (<1%), often associated with 
preeclampsia, present with greater weight deficit, abnormalities of fetal Doppler 
indices and more severe hypoxemia resulting in higher morbidity and mortality 
(38,40). In contrast, late-onset FGR is more common (3-5%), often occurs 
without concurrent maternal hypertension, less likely to have abnormal fetal 
Doppler indices but also associated with significant perinatal morbidity and 
mortality (38,40). The differing presentations of the same disorder (placental 
dysfunction) as two apparently distinct entities (early and late-onset FGR) are 
explained by the differing fetal nutritional and respiratory demands observed 
with advancing gestation (38,39,41). Fetal nutritional demands follow a 
logarithmic expansion whilst respiratory demands increase exponentially 
(Figure 3). As a consequence, early-onset placental dysfunction will have a 
disproportionate effect on fetal growth before respiratory compromise develops 
– hence fetal stunting is a characteristic feature of early-onset fetal growth 
restriction. In contrast, late-onset placental dysfunction will primarily 
compromise fetal respiratory function before fetal nutrition and growth are 




MANAGEMENT OF LATE-ONSET FETAL GROWTH RESTRICTION 
There appears to be effective early pregnancy screening for early-onset 
preeclampsia and fetal growth restriction. The ASPRE randomized double-blind 
placebo controlled trial in 1776 high-risk patients reported a reduction of 62% 
of early-onset preeclampsia with the use of 150mg aspirin from 16-36 weeks 
(42). In the ASPRE cohort, management of early-onset FGR is optimized using 
a combination of both computerized cardiotocography, fetal umbilical and 
ductus venous Doppler assessment interpreted using TRUFFLE criteria (30). 
The TRUFFLE study demonstrated a neurologically intact survival at 2-years of 
age in 95% of pregnancies presenting with early-onset FGR at 26-32 weeks’ 
gestation (30,31). However, no equivalent exists to screen for late-onset 
placental dysfunction and FGR near term, with the ASPRE and other screening 
algorithms performing poorly in this regard. In the absence of effective 
screening tools, detection of SGA near term is a substitute proxy target for 
many antenatal care protocols. The randomized blinded POPS study has 
clearly demonstrated that routine third-trimester ultrasound is three-times more 
effective that serial symphysis to fundal height measurement for the detection 
of SGA <3rd centile (11). 
The main limitation of an ultrasound-based programme for SGA detection at 
term is effectively differentiating physiologically small babies from SGA babies 
compromised by placental dysfunction (reducing false-positives) and 
identifying the burden of disease in placental dysfunction where fetuses are still 
normally-sized (reducing false-negatives). There is growing evidence here that 
the use of uterine, umbilical and middle cerebral artery Doppler indices - even 
in fetuses with AC/EFW above the 10th centile. These Doppler parameters have 
utility in detection of placental hypoperfusion (uterine Doppler) and fetal 
redistribution (umbilical and middle cerebral artery Doppler), as functional 
parameters with superior performance to isolated biometric measurements 
(39). Low cerebroplacental ratio (CPR) values in the third trimester of 
pregnancy has been shown to better reflect respiratory compromise and to be 
an independent predictor of stillbirth and perinatal mortality (43) - being at least 
two-times more predictive of adverse outcomes than fetal size alone (44). In 
this sense, it seems reasonable that multiple parameters should be assessed 
for a better prediction of fetuses at risk of stillbirth (43,45,46). Although the use 
of biomarkers such as PLGF and sFlt1 have been proved useful for prediction 
and timely diagnosis of preeclampsia (47,48), in pregnancies at 35-37 weeks 
of gestation the routine assessment of these markers provided poor prediction 
of perinatal outcomes in both SGA and non-SGA fetuses (49). Maybe the 
incorporation of these markers to more comprehensive algorithms should be 
the key to a better predictive performance regarding SGA and term stillbirth.  
Examples of the potential effectiveness of this approach have been shown in 
two recent studies. Akolekar et al, used 36 weeks ultrasound data in 45,000 
singleton pregnancies to identify fetuses with EFW <40th centile and stratify 
them into high, intermediate, low and very low-risk management groups 
according uterine, umbilical and middle cerebral artery pulsatility indexes (50). 
This approach identified 22% of women as moderate-high risk requiring further 
monitoring as this cohort contained 84% of adverse perinatal events occurring 
in term newborns with birthweight above the 10th centile. Other authors have 
proposed a multiparameter validated algorithm with the objective of identifying 
fetuses at high risk for fetal demise - the Individual RIsk aSsessment (IRIS) 
prediction model (51,52). The combination of three antenatal (gestational age, 
parity and CPR) and three intrapartum (epidural use, labor induction and 
oxytocin use) can be used to assess the risk for intrapartum compromise 
requiring operative delivery. The IRIS algorithm demonstrated moderate to 
good discrimination and no sign of poor fit – and is available as a smartphone 
app to aid clinical decision making regarding the mode of delivery for SGA 
fetuses (https://mail13240.wixsite.com/website). Whether such management 
protocols or algorithms could improve pregnancy outcome can only be 
evaluated in adequately powered, blinded trials. Nevertheless, it seems 
inevitable that in the future, algorithms combining maternal characteristics, fetal 
size, placental biomarkers and Doppler indices will become available to aid in 





Placental dysfunction has a deleterious influence on fetal size and is associated 
with higher rates of perinatal morbidity and mortality. This observation has 
underpinned the evaluation of fetal size as the conventional strategy to identify 
placental dysfunction and prevent stillbirth. An effective policy of SGA detection 
requires routine third trimester ultrasound, EFW estimation using the Hadlock 
HC-AC-FL formula and evaluation of the fetal EFW centile using an 
international fetal growth standard such as INTERGROWTH-21st. However, 
this strategy is undermined by recent data which demonstrates that the 
relationship between fetal size and adverse outcome weakens significantly with 
advancing gestation such that near term, the majority of stillbirths and adverse 
perinatal outcomes occur in normally-sized fetuses. The use of fetal Doppler 
and maternal serum biochemical parameters near term appear to be a superior 
to fetal size in the identification of fetuses compromised by placental 
dysfunction and at risk of demise. Such multiparameter models and algorithms 
using maternal risk factors, biochemical and Doppler parameters have been 
developed, but need to be prospectively validated to demonstrtate their 
effectiveness.  
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Figure 1. Stillbirth rate according to birthweight centiles [adapted from 
Iliodromiti et al. (23)]. 
Figure 2. Birth weight according to gestational age at delivery in 436 
pregnancies complicated by stillbirth, plotted against the 10th, 50th and 90th 
centiles of a multiethnic population of 113,456 women normal range (solid lines) 
and those of the INTERGROWTH-21st standard (dotted lines). Adapted from 
Poon et al. (29). 
Figure 3. Increase in fetal nutritional (green line) and respiratory (red line) 
demands with advancing gestation [adapted from Thilaganathan B. (39)]. Early-
onset placental dysfunction (vertical gray solid line) will impact at a time when 
fetal nutritional demands (green arrows) rise exponentially and therefore will 
have a disproportionate effect on fetal growth compared with development of 
fetal hypoxemia and demise. Placental dysfunction at term (vertical gray dotted 
line) will impact at a time when fetal respiratory needs (red arrows) rise 
exponentially and therefore likely to compromise fetal wellbeing before fetal 
growth is impaired. 
  
Table 1. Delphi consensus-based definitions for early and fetal growth 
restriction (FGR) in absence of congenital anomalies [adapted from Gordijn et 
al. (37)]. 
Early FGR: 
GA < 32 weeks in absence of congenital 
anomalies 
Late FGR: 
GA  32 weeks in absence of congenital 
anomalies 
AC/EFW < 3rd centile or UA-AEDF 
Or 
1. AC/EFW < 10th centile combined with 
2. UtA-PI > 95th centile and/or 
3. UA-PI > 95th centile 
AC/EFW < 3rd centile 
Or at least 2 out of 3 of the following 
1. AC/EFW < 10th centile 
2. AC/EFW crossing centiles > 2 quartiles 
on growth centiles* 
3. CPR < 5th centile or UA-PI > 95th centile 
* Growth centiles are non-customized centiles. AC = fetal abdominal circumference; AEDF = absent end-
diastolic flow; CPR = cerebroplacental ratio; EFW = estimated fetal weight; GA = gestational age; PI = 
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Figure 3. Increase in fetal nutritional (green line) and respiratory (red line) 
demands with advancing gestation [adapted from Thilaganathan B. (39)]. Early-
onset placental dysfunction (vertical gray solid line) will impact at a time when 
fetal nutritional demands (green arrows) rise exponentially and therefore will 
have a disproportionate effect on fetal growth compared with development of 
fetal hypoxemia and demise. Placental dysfunction at term (vertical gray dotted 
line) will impact at a time when fetal respiratory needs (red arrows) rise 
exponentially and therefore likely to compromise fetal wellbeing before fetal 
growth is impaired. 
